Exclusive: Oxford study indicates AstraZeneca effective against Brazil variant, source says




  • In Science
  • 2021-03-05 14:40:35Z
  • By Reuters
 

By Rodrigo Viga Gaier

RIO DE JANEIRO (Reuters) - Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or Brazilian, variant, a source with knowledge of the study told Reuters on Friday.

The data indicates that the vaccine will not need to be modified in order to protect against the variant, which is believed to have originated in the Amazonian city of Manaus, said the source, who requested anonymity as the results have not yet been made public.

The source did not provide the exact efficacy of the vaccine against the variant. They said the full results of the study should be released soon, possibly in March.

Early results indicated the AstraZeneca vaccine was significantly less effective against the South African variant, which is similar to P1. South Africa subsequently paused the use of the vaccine in the country.

The information comes as a plasma study published ahead of peer review on Monday (https://bit.ly/3bX3LBa) suggested the CoronaVac COVID-19 vaccine developed by China's Sinovac Biotech may not work effectively against the Brazilian variant.

Responding to a request for comment, Fiocruz, which sent the samples that formed the basis of the AstraZeneca vaccine study, told Reuters it did not have any information on the study, as it was being led by AstraZeneca and the University of Oxford.

Representatives for AstraZeneca and the University of Oxford did not immediately respond to requests for comment.

Brazil is currently confronting a brutal and long-lasting second wave of the coronavirus, hitting a daily record of 1,910 deaths on Wednesday.

The P1 variant (also known as 20J/501Y.V3) is among the factors that epidemiologists believe is contributing to a rise in cases and deaths, and there has been concern in the scientific community about the variant's resistance to vaccines.

COMMENTS

More Related News

Angela Merkel got a shot of the AstraZeneca vaccine amid Germany
Angela Merkel got a shot of the AstraZeneca vaccine amid Germany's faltering rollout. She once said she wouldn't, and then the rules changed.

Merkel got the shot in Berlin on Friday, following several German concerns over AstraZeneca's rollout, efficacy and reports of blood clots.

Countries seek more Moderna, Pfizer/BioNTech COVID-19 shots as concerns mount over rival vaccines
Countries seek more Moderna, Pfizer/BioNTech COVID-19 shots as concerns mount over rival vaccines
  • US
  • 2021-04-16 11:03:48Z

Wealthy governments are looking to COVID-19 shots from Pfizer Inc and Moderna Inc to keep their vaccination programs on track, as safety concerns and...

Analysis: India shifts from mass vaccine exporter to importer, worrying the world
Analysis: India shifts from mass vaccine exporter to importer, worrying the world

After gifting and selling tens of millions of COVID-19 vaccine doses abroad, India suddenly finds itself short of shots as new infections surge in the...

COVID-19 itself could cause blood clots much more often than vaccines, data shows, as regulators wrestle with pausing rollouts
COVID-19 itself could cause blood clots much more often than vaccines, data shows, as regulators wrestle with pausing rollouts

This data should be used to guide countries which have decided to limit the use of some COVID-19 vaccine, the scientists said.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Science